Compare BridgeBio Pharma Inc (BBIO) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Nebius Group NV — how do they compare? BridgeBio Pharma Inc trades at $84.12 (market cap $16.46B), while Nebius Group NV trades at $200.33 (market cap $49.28B). The key difference: Nebius Group NV is far larger — about 3× BridgeBio Pharma Inc's market cap, and BridgeBio Pharma Inc is trading nearer its 52-week high, Nebius Group NV nearer its low. Which is the better fit depends on your goals.
| BBIO | NBIS | |
|---|---|---|
Market Cap | $16.46B | $49.28B |
Sector | Health | Technology |
52-Week High | $90.17 | $286.69 |
52-Week Low | $44.81 | $50.40 |
Enterprise Value | $18.02B | $49.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.
Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.
NBIS trades at $210.51, down 4.16% today amid bearish technical signals, though it maintains strong analyst support with 87.5% buy ratings and a $248 consensus price target. The company shows impressive revenue growth projections from $530M in 2025 to $878M in 2026, with net income margin expanding to 93.09%. Recent positive developments include a $1 billion compute deal with Reflection AI and strategic infrastructure expansion, though valuation ratios remain elevated with P/E at 74.94.
The outlook remains constructive given robust AI infrastructure demand and significant contract wins, but investors face risks from Meta's potential cloud competition and high valuations. Near-term price action suggests consolidation near support at $204, with upside potential to resistance at $218 if earnings momentum continues.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
